Verona Pharma
plc
("Verona Pharma" or the
"Company")
Directorate
Change
11 January 2016, Cardiff –
Verona Pharma plc (AIM: VRP.L), the drug development company
focused on first-in-class medicines to treat respiratory diseases,
announces the resignation of Biresh
Roy, Chief Financial Officer of the Company. He will step
down from the Board with immediate effect but will remain with
Verona Pharma for up to six months to allow time for a suitable
successor to be appointed and for an orderly handover. The Board
has commenced a search for his successor and a further announcement
will be made in due course.
Dr. David Ebsworth, Chairman of
Verona Pharma, said: “The Board would like to thank Biresh for his
many contributions to the Company. This has been a particularly
formative time for Verona Pharma as it has delivered on important
operational and clinical goals it set at the time of the 2014
Financing in a timely manner. Importantly, Biresh’s financial
stewardship has also ensured that these goals have been met on, or
ahead of, budget. We warmly wish Biresh all the best in his future
endeavours.”
-Ends-
For further information please
contact:
Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer |
Tel: +44 (0)20 3283 4200 |
N+1 Singer
Aubrey Powell / Jen Boorer |
Tel: +44 (0)20 7496 3000 |
FTI Consulting
Simon Conway / Stephanie Cuthbert /
Natalie Garland-Collins |
Tel: +44 (0)20 3727 1000 |
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase II trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for
COPD and asthma maintenance therapy. The Company is also
exploring the potential of the drug in different diseases, such as
cystic fibrosis, where it is in pre-clinical testing and has
received a Venture and Innovation Award from the Cystic Fibrosis
Trust.